RITALIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for RITALIN (RITALIN).
Methylphenidate is a central nervous system stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons by inhibiting the dopamine transporter (DAT) and norepinephrine transporter (NET), increasing their synaptic concentrations.
| Metabolism | Primarily hepatic via carboxylesterase CES1A1 to the inactive metabolite ritalinic acid. Minor pathways include hydroxylation and oxidative metabolism. CYP2D6 plays a minor role. |
| Excretion | Renal: 80-90% (as unchanged drug and metabolites, primarily ritalinic acid); Fecal: <1%; Biliary: minimal |
| Half-life | 3-4 hours (immediate-release); 6-8 hours (sustained-release); clinical context: requires multiple daily dosing for sustained effect |
| Protein binding | 10-33% bound to albumin and α₁-acid glycoprotein |
| Volume of Distribution | 0.2-0.5 L/kg (low Vd, reflects limited tissue distribution) |
| Bioavailability | Oral: 20-30% (due to first-pass metabolism); Intravenous: 100% |
| Onset of Action | Oral immediate-release: 20-30 minutes; Oral sustained-release: 1-2 hours; Intravenous: <5 minutes |
| Duration of Action | Immediate-release: 3-4 hours; Sustained-release: 8-12 hours; clinical notes: shorter duration with immediate-release may require multiple doses |
Initial: 5 mg orally twice daily (before breakfast and lunch); increase by 5-10 mg weekly; maximum 60 mg/day.
| Dosage form | TABLET |
| Renal impairment | No specific guidelines; use with caution in severe renal impairment (GFR <30 mL/min). |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use. |
| Pediatric use | Children ≥6 years: initial 5 mg orally twice daily; increase by 5 mg weekly; max 60 mg/day; <6 years: not recommended. |
| Geriatric use | Start at 2.5 mg twice daily; increase slowly; monitor for hypertension, insomnia, and agitation. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for RITALIN (RITALIN).
| Breastfeeding | Methylphenidate is excreted into breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 2.5. Peak milk concentration occurs 1-2 hours after oral dosing. Relative infant dose is estimated at 0.2-1.6% of maternal weight-adjusted dose. A single case report noted no adverse effects in breastfed infants, but long-term neurodevelopmental data are lacking. Caution advised; monitor infant for agitation, insomnia, and poor feeding. |
| Teratogenic Risk | First trimester: Limited human data; animal studies at high doses show increased risk of malformations (e.g., orofacial clefts, neural tube defects). Second and third trimesters: Potential for increased risk of preterm birth, low birth weight, and neonatal withdrawal syndrome (irritability, tachycardia, poor feeding). A causal relationship in humans has not been definitively established; risk-benefit assessment is essential. |
■ FDA Black Box Warning
Methylphenidate has a high potential for abuse and dependence. Prolonged use may lead to drug dependence. Misuse may cause sudden death or serious cardiovascular adverse events.
| Serious Effects |
["Hypersensitivity to methylphenidate or any component of the formulation","Concurrent treatment with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI","Glaucoma","Severe anxiety, tension, or agitation","Tourette's syndrome or tics (relative contraindication)","Hyperthyroidism","Severe hypertension or other cardiovascular disease such as arrhythmias"]
| Precautions | ["Risk of serious cardiovascular events including sudden death in patients with structural cardiac abnormalities or other serious heart problems","Increased blood pressure and heart rate","Psychiatric adverse events including exacerbation of pre-existing psychosis, mania, and aggression","Potential for growth suppression in children; monitor height and weight","Risk of priapism","May lower seizure threshold","Peripheral vasculopathy including Raynaud's phenomenon"] |
Loading safety data…
| Fetal Monitoring | Maternal: Baseline and periodic monitoring of heart rate, blood pressure, and weight; assessment for signs of abuse or dependence; fetal: serial ultrasound for growth restriction if used chronically; neonatal monitoring for withdrawal symptoms (e.g., irritability, hypertonia, poor feeding) for 48-72 hours postpartum. |
| Fertility Effects | In animal studies, high doses of methylphenidate have been associated with reduced fertility and increased postimplantation loss in females; in males, decreased sperm motility and concentration have been reported. Human data are insufficient to determine effects on fertility; however, caution is advised in patients attempting conception. |